

ÖZGÜR ŞAHİN, PhD

ACADEMIC POSITIONS

09/2013-Current

Assistant Professor (Tenure-track), [Bilkent University](#), Department of Molecular Biology and Genetics, Ankara, TURKEY

01/2012 – 08/2013

Instructor (research faculty), [UT MD Anderson Cancer Center \(MDACC\)](#), Department of Molecular and Cellular Oncology, Houston, TX, USA

09/2008 – 12/2011

Research group leader, [German Cancer Research Center \(DKFZ\)](#), Division of Molecular Genome Analysis, [RTK Signaling Group](#), Heidelberg, GERMANY

EDUCATION

06/2005 – 05/2008

Ph.D. (*summa cum laude*) Division of Molecular Genome Analysis, [German Cancer Research Center \(DKFZ\)](#) and [University of Heidelberg](#), GERMANY.

PhD thesis on "A systems biology approach for identification of novel targets and validations *via* combinatorial RNAi in trastuzumab resistant breast cancer".

10/2003 – 04/2005

M.Sc. (honor) International Molecular and Cellular Biology Program, [University of Heidelberg](#) and [German Cancer Research Center \(DKFZ\)](#), Heidelberg, GERMANY.

Master thesis on "Examination of non-characterized proteins on their influence to metastasis-related processes".

09/1999 – 06/2003

B.Sc. (high honor) Molecular Biology and Genetics [Middle East Technical University](#). Ankara, TURKEY. *GPA: 3.75:4.00 Rank:3/21*

Bachelor thesis on "Controlled release of analgesics from PHBV-PLGA nanospheres".

06/2002 – 08/2002

Research internship Institute for Biomedical Engineering, [Swiss Federal Institute of Technology \(EPFL\)](#), Lausanne, SWITZERLAND

Project on "Optimization of successive steps in Real Time RT-PCR for osteoblast gene expression studies".

09/1998 – 06/1999

English Preparatory School, [Middle East Technical University](#). Ankara, TURKEY

09/1994 – 02/1997

High School, Kocasinan Atatürk Lisesi, Kayseri, TURKEY *GPA: 4.91:5.00 Rank: 1/250*

LANGUAGES

Native Language	Turkish
Foreign Languages	English, German

GRANTS (on-going)

01/2014-12/2018

EMBO Installation Grants

“Systems biology of drug resistance and organ-specific metastasis in breast cancer”

Role: Principal investigator

Amount: 250.000 Euros for 5 years

07/2014-06/2018

Marie Curie Career Integration Grants

“Enhancing chemotherapy response in triple negative breast cancer (TNBC) by modulating miRNA-protein networks and identifying biomarkers of response”

Role: Principal investigator

Amount: 100.000 Euros for 4 years

04/2015-04/2018

TUBITAK 1001 Grant

“Combinatorial targeting of PI3K and MAPK signaling pathways by microRNAs to inhibit tumor growth and metastasis in breast cancer”

Role: Principal investigator

Amount: 344.267 TL for 3 years

05/2015-05/2017

TUBITAK-CNRS (France) Bilateral Grant

“Identifying and targeting sponge long non-coding RNAs to inhibit metastasis in triple negative breast cancer using a systems biology approach”

Role: Principal investigator

Amount: 355.569 TL for 2 years

06/2016-05/2018

Ministry of Science, Industry and Technology SAN-TEZ Grant

“Developing a theranostic kit predicting treatment response and determining personalized treatment options in TNBC”

Role: Principal investigator

Amount: 1.761.352 TL for 2 years

05/2016-04/2018

TUBITAK 1001 Grant

“Identifying and targeting long non-coding RNAs in playing role in tamoxifen resistance in ER-positive breast cancer using in vitro and in vivo assays”

Role: Principal investigator

Amount: 359.282 TL for 2 years

GRANTS (completed)

02/2014-01/2016

TUBITAK 2232 Grant

“Targeting miRNA-protein networks to enhance chemotherapy response in BRCA1-mutated triple negative breast cancer”

Role: Principal investigator

Amount: 25.000 TL for 2 years

01/2012 - 08/2012

MD Anderson Cancer Center Breast SPORE - Career Development Award

“Contribution of immune responses to the reversal of trastuzumab resistance by combinatorial targeted therapies”

Role: Principal investigator

Amount: 50.000 \$/year for 1 year

08/2010 - 08/2012

Wilhelm-Sander Stiftung

“The effects of microRNAs on the feedback regulation of ErbB signaling in breast cancer: Implications for therapy”

Role: Principal investigator, Evaluated as ‘VERY GOOD’

Amount: 100.000 Euros for 2 years

09/2008 - 05/2011

National Genome Research Network (NGFN) Plus

IG-Cellular Systems Genomics: Signaling network analysis in drug resistant breast cancer

Role: Co-investigator

Amount: 3 million Euros for 5 years

HONORS, AWARDS and SCHOLARSHIPS

06/2016	Scientist of the Year 2015 Award from Bilim Kahramanları Association
06/2014	Outstanding Young Scientist (GEBIP) Award from Turkish Academy of Sciences
03/2014	Young Scientist Award (BAGEP) from Science Academy
09/2011	Poster award-oral presentation from UT MD Anderson Cancer Center , Symposia on Cancer Research 2011
05/2010	Leistungsprämie - best performance fee from President of German Cancer Research Center (DKFZ)
05/2008	PhD degree with “ <i>summa cum laude - excellent</i> ”
10/2004 – 03/2005	Master Thesis Scholarship from German Cancer Research Center (DKFZ)
10/2003 – 09/2004	MCB Master Programme scholarship from the University of Heidelberg
09/1998 – 06/2003	Basic Science scholarship from Scientific and Technical Research Council of Turkey and Middle East Technical University for being in 0.1% of all the examinee in the university entrance exam (ÖYS)
09/1998 – 06/2003	7 high honor and 1 honor degree during undergraduate education
06/1997	Finishing high school with the first degree and being awarded by Mayor of Kayseri

ACADEMIC CONFERENCES & MEETINGS ATTENDED**Organized events:**

- 11/2015** The 4th International Congress of Molecular Biology Association of Turkey, with the participation of 400 scientists. November 27-29, 2015. Ankara, TURKEY
- 01/2015** EMBO-MBD sponsored Winter Retreat with the participation of 150 scientists from Turkey. January 16-17, 2015. Ankara, TURKEY

Invited talks:

- 06/206** Invitation to the EMBO Cancer Young Investigator Program Meeting, Heraklion, GREECE
- 11/2015** Invitation by Prof. Hakan Akbulut, Ankara University Oncology Institute, Ankara, TURKEY
- 10/2015** Invitation as a speaker to the 3rd International BAU Drug Design Congress, İstanbul, TURKEY
- 05/2015** Invitation to the EACR Sponsored 3rd International Anticancer Development Congress, Izmir, TURKEY.
- 05/2015** Joint Workshop on Molecular Biology with Singapore, Ankara, TURKEY
- 01/2015** Invitation by Prof. Florian Haller, University of Erlangen, January 27, 2015, Erlangen, GERMANY.
- 09/2014** Invitation as an invited speaker to the 3rd International Congress of Turkish Molecular Biology Association, Izmir, TURKEY
- 06/2014** Invitation to Working Group on Cancer Meeting by Turkish Academy of Sciences, Istanbul, TURKEY
- 05/2014** Invitation by Prof. Mehmet Ozturk, Advanced Biomedical Research Center, Izmir, TURKEY
- 04/2014** Invitation by Bilkent undergraduate students to Horizons In Molecular Biology and Genetics VI Conference, Ankara, TURKEY
- 02/2014** Invitation by Hacettepe Oncology Institute, Ankara, TURKEY
- 09/2013** Invitation as a keynote speaker to the HIBIT 2013 Meeting in Ankara, TURKEY
- 08/2013** Invitation by Prof Jos Jonkers, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
- 02/2013** Invitation by Prof John Dawson, University of South Carolina, Columbia, SC, USA (tenure-track faculty interview—position offered/declined)
- 11/2012** Invitation by Prof Tayfun Ozcelik, Bilkent University, Ankara, TURKEY (tenure-track faculty interview—position offered/accepted)
- 07/2011** Invitation by Asst Prof Devrim Gözüacik, Sabanci University, Istanbul, TURKEY.
- 12/2010** Invitation by Prof Emmanuel Barillot, Institut Curie, Paris, FRANCE.

- 12/2010** Invitation by Prof Jean Imbert, INSERM, Marseille, FRANCE.
- 09/2010** Invitation by “Systems Genomics 2010” in Heidelberg, GERMANY.
- 05/2010** “Invitation by PD Dr Florian Haller, Institute for Pathology, Albert Ludwigs University, Freiburg, GERMANY.
- 07/2010** Invitation by Assoc Prof Yusuf Baran, Izmir Institute of Technology, Izmir, TURKEY.
- 11/2009** Invitation by European Science Foundation- GPCR Signalling Systems: A New Avenue For Drug Discovery? in Paris, FRANCE.
- 06/2009** Invitation by Bayer in Berlin, GERMANY.
- 02/2009** Invitation by MERCK in Darmstadt, GERMANY.

Selected talks:

- 09/2011** “Symposia on Cancer Research 2011”, UT MD Anderson Cancer Center, Houston, TX, USA
- 09/2010** “German-Israeli DIP Meeting”, Weizmann Institute, Rehovot, ISRAEL.
- 11/2009** “National Genome Research Network (NGFN) Meeting “ in Berlin, GERMANY.
- 03/2008** “The 31st Meeting of German Society for Cell Biology (DGZ)” in Marburg, GERMANY.
- 11/2007** “National Genome Research Network Meeting “ in Heidelberg, GERMANY.
- 09/2007** “The 9th DGZ Young Scientist Meeting - Signaling Cascades in Development and Disease “ in Münster, GERMANY.
- 02/2007** “Collaborative meeting on modeling using GINsim” in Marseille, FRANCE.
- 09/2006** ”Genomics and Cancer Conference” in Heidelberg, GERMANY.

Poster presentations (only as first or last author):

- 04/2015** “American Association for Cancer Research (AACR) Annual Meeting” in Philadelphia, USA.
- 07/2014** “European Association for Cancer Research (EACR) Bi-annual Meeting” in Munich, GERMANY.
- 04/2013** “American Association for Cancer Research (AACR) Annual Meeting” in Washington DC, USA.
- 10/2012** “CPRIT’s 3rd Annual CPRIT Innovations in Cancer Prevention and Research Conference” in Austin, TX, USA.
- 06/2010** “21st meeting of the European Association for Cancer Research (EACR-21)” in Oslo, NORWAY.
- 06/2010** “The Systems Biology of Mammalian Cells Conference” in Freiburg, GERMANY.
- 12/2009** “The 49th Meeting of American Society of Cell Biology (ASCB)” in San Diego, USA.

03/2009	“The 15 th International AEK Cancer Congress” in Berlin, GERMANY.
12/2008	“The 48 th Meeting of American Society of Cell Biology (ASCB)” in San Francisco, USA.
05/2008	“Systems Genomics Conference” in Heidelberg, GERMANY.
10/2007	“The 8 th International Conference on Systems Biology “ in Long Beach, USA.
05/2007	“European BioPerspectives 2007” in Cologne, GERMANY.
11/2006	“National Genome Research Network Meeting” in Heidelberg, GERMANY.
10/2006	“The 7 th International Conference on Systems Biology” in Yokohama, JAPAN.
12/2005	“International PhD Students Poster Contest” by German Cancer Research Center. GERMANY.
09/2005	“ELSO 2005 - Frontiers of cellular, developmental and molecular biology” in Dresden, GERMANY.

TEACHING ACTIVITIES

09/2013-Current

MBG309 Principles of Biochemistry
 MBG311 Biochemistry I
 MBG603 Molecular Bases of Cancer
 MBG110 Introduction to Modern Biology
 MBG509 Special Topics in Molecular Biology I
 MBG612 Special Topics in Genetics I
 MBG491 Senior Project I
 MBG492 Senior Project II

01/2009 – 12/2011

Faculty member of DKFZ “Major Cancer Biology” Master’s Program

SUPERVISED DISSERTATIONS as primary advisor

11/2008 – 09/2009

Anja Schwäger, M.Sc.

“MicroRNA-200c modulates epidermal growth factor receptor signaling by targeting the feedback regulator mitogen-inducible gene 6” Grade: 1.0/1.0

Current position: PhD student at Karolinska Institute, Stockholm, SWEDEN

03/2010- 09/2010

Marek Baumann, M.Sc.

“MicroRNA-200c represses migration of breast cancer cells by targeting a network of GTPases”
 Grade: 1.0/1.0

Current position: PhD student at Technische Universität Dresden (TUD), Dresden, GERMANY

03/2010 - 12/2010

Aysenur Torun, M.Sc.

“MicroRNA-203 regulates breast cancer cell migration by targeting SRC and CAV-1”

Grade: 1.3/1.0

Current position: Postgraduate research associate at Yale University, New Haven, CT, USA

12/2010 - 07/2011

Sarah Jurmeister, M.Sc.

“miR-200c represses migration of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F” Grade: 1.0/1.0

Current position: PhD student at University of Cambridge, Cambridge, UK

11/2008 - 09/2012

Stefan Uhlmann, PhD

“MicroRNA regulation of the EGFR signaling pathway in breast cancer”

Grade: *magna cum laude*

Current position: PostDoc at Universitaetklinikum Heidelberg, Heidelberg, GERMANY

11/2009 - 05/2013

Aoife Ward, PhD

“The role of microRNAs in resistance to targeted therapies in breast cancer”

Grade: *magna cum laude*

Current position: PostDoc at German Cancer Research Center, Heidelberg, GERMANY

03/2010 - 10/2015

Aleksandra Balwierz, PhD (co-supervision with Dr. Stefan Wiemann, DKFZ, Heidelberg)

“ERBB2 as a driver of an invasive phenotype of cells grown in 3D culture and an important regulator of oncogenic miRNAs’ expression in breast cancer”

Grade: *magna cum laude*

10/2013 - 07/2016

Merve Mutlu, M.Sc.

“Combinatorial targeting of PI3K and MAPK pathways by miR-564 to inhibit proliferation and invasion in breast cancer”

Current position: PhD Student at University of Bern, Bern, SWITZERLAND

11/2013 - 08/2016

Özge Saatci, M.Sc.

“Elucidating the mechanisms of T-DM1 resistance in *in vitro* models of HER2 overexpressing breast cancer”

Current position: PhD Student at Bilkent University, Ankara, TURKEY

11/2013 - 08/2016

Erol Eyüpoğlu, M.Sc.

“Targeting miRNA-protein regulatory networks to enhance chemotherapy response in BRCA1-mutated TNBCs”

Current position: PhD Student at Bilkent University, Ankara, TURKEY

ON-GOING DISSERTATIONS

Umar Raza, PhD student

Pelin Ersan, PhD student

Ünal Metin Tokat, PhD student

Özge Akbulut, PhD student

Özge Saatçi, PhD student

Erol Eyüpoğlu, PhD student

Hilal Bal, Master student

SCIENTIFIC ACTIVITIES

Active member of American Association for Cancer Research (AACR)
 Member of European Association for Cancer Research (EACR)
 Member of American Society for Cell Biology (ASCB)
 Member of Turkish Medical Biology and Genetics Society
 Member of Turkish Molecular Cancer Research Association (MOKAD)
 Editorial board member for The Journal of Cancer Therapeutics and Research (JCTR)
 Reviewer of U.S. - Israel Binational Science Foundation (BSF)
 Reviewer of Italian Association for Cancer research (AIRC)
 Panelist for TUBITAK grants
 PhD Examiner at Karolinska Institute (2014)
 President of Student Council of METU Biological Sciences Faculty (2002-2003)

PEER-REVIEWED PUBLICATIONS

* *indicates corresponding author*

5 selected publications:

1. Uhlmann S, Mannsperger H, Zhang JD, Horvath EA, Schmidt S, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, **Sahin Ö*** (2012). Global microRNA level regulation of EGFR-driven cell cycle protein network in breast cancer. *Mol Syst Biol.* 8:570. (Featured article) (**Impact Factor: 14.1**)
2. **Sahin Ö**, Wang Q, Brady S, Ellis K, Wang H, Li P, Chang C, Zhang Q, Priya P, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D (2014). Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. *Cell Research.* 24(5):542-59. (**Impact Factor: 12.0**)
3. **Sahin Ö**, Löbke C, Korf U, Appelhans H, Sülthmann H, Poustka A, Wiemann S, Arlt D (2007) Combinatorial RNAi for quantitative protein network analysis. *PNAS.* 104:6579-6584. (Highlighted in the Issue). (**Impact Factor: 9.6**)
4. Xu J, Acharya S, **Sahin Ö**, Wang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery F, Kuo W, Xiao Y, Ensor J, Sahin A, Zhang X, Hung M, Zhang JD, Yu D (2015). 14-3-3 ζ turns TGF- β 's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. *Cancer Cell.* 27(2):177-92. (**Impact Factor: 23.9**)
5. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, **Sahin Ö*** (2013). Re-expression of microRNA375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. *Oncogene.* 32(9):1173-82 (**Impact Factor: 8.6**)

All publications in reverse chronological order**2016**

1. Mutlu M, Saatci Ö, Ansari SA, Yurdusev E, Shehwana H, Konu Ö, Raza U, **Sahin Ö*** (2016). miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. *Scientific Reports.* doi:10.1038/srep32541.
2. Raza U, Saatci Ö, Uhlmann S, Ansari SA, Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK, Zhang JD, Doğan HT, Güler G, **Sahin Ö*** (2016). The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell

survival and epithelial-mesenchymal transition in breast cancer. ***Oncotarget***. doi: 10.18632/oncotarget.10489.

3. Chang C, Zhang C, Zhang Q, **Sahin Ö**, Wang H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, Hung M-C, Behbod F, Yu D. Upregulation of Lactate Dehydrogenase A by 14-3-3 ζ Leads to Increased Glycolysis Critical for Breast Cancer Initiation and Progression. ***Oncotarget***. doi: 10.18632/oncotarget.9136.
4. Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E, Yurdusev E, **Sahin Ö*** (2016). miR-200c: A versatile watchdog in cancer progression, EMT and drug resistance. ***Journal of Molecular Medicine*** (invited review). doi 10.1007/s00109-016-1420-5.

2015

5. Xu J, Acharya S, **Sahin Ö**, Wang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery F, Kuo W, Xiao Y, Ensor J, Sahin A, Zhang X, Hung M, Zhang JD, Yu D (2015). 14-3-3 ζ turns TGF- β 's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. ***Cancer Cell***. 27(2):177-92.
6. Haller F, Zhang JD, Moskalev E, Braun A, Otto C, Geddert H, Riazalhosseini Y, Ward A, Balwierz A, Cameron S, Korn B, Shaefer I, Cameron S, Agaimy A, Fletcher JA, Hoheisel J, Hartmann A, Werner M, Wiemann S, **Sahin Ö** (2015). Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors (GISTs) reveals hypomethylation of SPP1 as an independent prognostic factor. ***International Journal of Cancer***. 136(5):1013-23.

2014

7. Ward A, Balwierz A, Soons Z, König R, **Sahin, Ö**, Wiemann S (2014). MicroRNA-519 is a novel oncomir conferring tamoxifen resistance by targeting a network of cell cycle genes in ER (+) breast cancer. ***Journal of Pathology***. doi: 10.1002/path.4363.
8. **Sahin Ö**, Wang Q, Brady S, Ellis K, Wang H, Li P, Chang C, Zhang Q, Priya P, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. ***Cell Research***. 24(5):542-59.
9. Raza U, Zhang JD, **Sahin Ö**. (2014) MicroRNAs: Master regulators of drug resistance, stemness and metastasis. ***Journal of Molecular Medicine*** (invited review). 2014 Apr;92(4):321-36.
10. Rehman SK, Li SH, Wyszomierski SL, Wang Q, **Sahin Ö**, Xiao Y, Li P, Zhang S, Xiong Y, Yang J, Guo H, Wang H, Medina D, Muller WJ, Yu D. (2014) 14-3-3zeta orchestrates mammary tumor onset and progression *via* miR221-mediated cell proliferation. ***Cancer Research***. Jan 1;74(1):363-73.

2013

11. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, **Sahin Ö*** (2013). Re-expression of microRNA375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. ***Oncogene***. 32(9):1173-82.
12. Shahmoradgoli M, Riazalhosseini Y, Haag D, Hovestadt V, Becker N, Mannherz O, Sinn HP, Schneeweiss A, **Sahin Ö**, Lichter P. (2013) Protein phosphatase 1, regulatory subunit 15B, PPP1R15B, is a survival factor rendering resistance in ER α -positive breast cancer. ***Int. J Cancer***. 132(11):2714-9.
13. Horvat EA, Zhang JD, Uhlmann S, **Sahin Ö**, Zweig KA. (2013) A network-based method to assess the statistical significance of mild co-regulation effects. ***Plos ONE***. 8(9): 8(9):e73413.

14. Issa A, Gill JW, **Sahin Ö**, Wiemann S, Dey J and Hynes NE (2013). Combinations of FGF and ErbB receptor inhibitors in breast cancer models block Erk and PI3K signaling, tumor growth and metastatic spread. *Breast Cancer Res.* 15(1):R8.
15. Botla SK, Gholami AM, Malekpour M, Moskalev EA, Fallah M, Jandaghi P, Aghajani A, Bondar IS, Omranipour R, Malekpour F, Mohajeri A, Babadi AJ, **Sahin Ö**, Bubnov VV, Najmabadi H, Hoheisel JD, Riazalhosseini Y.(2013) Diagnostic values of *GHSR* DNA methylation pattern in breast cancer. *Breast Can Res and Treat.* 135(3):705-13.

2012

16. Uhlmann S, Mannsperger H, Zhang JD, Horvath EA, Schmidt S, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, **Sahin Ö*** (2012). Global microRNA level regulation of EGFR-driven cell cycle protein network in breast cancer. *Mol Syst Biol.* 8:570. (Featured article)
 - Comment in News&Views by Malumbres (2012), *Mol Syst Biol*, **8:569**.
17. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S*, **Sahin Ö*** (2012). MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. *Mol Cell Biol.* 32(3):633-51.
18. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, **Sahin Ö**, Wiemann S, Tschulena U (2012). MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF- κ B and TGF- β signaling pathways. *Oncogene.* 31(37):4150-63.
19. Wang Q, Li S, Wang H, Xiao Y, **Sahin Ö**, Brady SW, Li P, Xiong Y, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D (2012). Concomitant targeting of tumor cells and induction of T cell response synergizes to inhibit trastuzumab-resistant breast cancer. *Cancer Research.* 72(17):4417-28.

2011

20. Zhang JD, Koerner C, Bechtel S, Bender C, Keklikoglou I, Schmidt C, Irsigler A, Ernst U, **Sahin Ö**, Wiemann S, Tschulena U (2011). Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. *PLoS ONE.* 6(7):e22176.

2010

21. Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, **Sahin Ö*** (2010). miR-200bc/429 cluster targets PLC γ 1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. *Oncogene.* 29(30):4297-306.
22. Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, Ramadori G, Wiemann S, **Sahin Ö** (2010). Localisation- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs) with a cluster of coexpressed miRNAs located at 14q32.31. *Journal of Pathology.* 220(1):71-86.
23. Mannsperger HA, Uhlmann S, Schmidt C, Wiemann S, **Sahin Ö** and Korf U (2010). RNAi-based validation of antibodies for reverse phase protein arrays. *Proteome Science.* 8(1):69.
24. Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, **Sahin Ö**, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y (2010). Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with Estrogen Receptor α in breast cancer cells. *Cancer Research.* 70(22):9175-84.

2009

25. **Sahin Ö***, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, Poustka A, Wiemann S, Beissbarth T, Arlt D* (2009). Modeling

ERBB receptor regulated G1/S transition network in de novo trastuzumab resistant breast cancer. *BMC Systems Biology*. 3:1. (Indicated as highly accessed on BioMed Central).

26. Fröhlich H , Sahin Ö, Arlt D, Bender C, Beissbarth T (2009). Deterministic effects propagation networks for reconstructing protein signaling networks from multiple interventions. *BMC Bioinformatics*. 10:322.
27. Sahin Ö and Wiemann S (2009) Functional genomics and proteomics approaches to study the ERBB-network in cancer. (Review). *FEBS Lett* 583(11):1766-71. (invited)
28. Korf U, Löbke C, Sahin Ö, Haller F, Sülthmann H, Arlt D, Poustka A (2009) **Reverse phase protein arrays (RPPA) for application-orientated cancer research** (Review). *Proteomics - Clinical Applications*. 3(10): 1140–1150.

2008

29. Sauermaun M, Sahin Ö, Sülthmann H, Hahne F, Blaszkiewicz S, Majety M, Zatloukal K, Füzesi L, Poustka A, Wiemann S, Arlt D (2008) Reduced expression of Vacuole membrane protein 1 (Vmp1) affects the invasion capacity of tumor cells. *Oncogene*. 27(9):1320-6.
30. Löbke C, Laible M, Rappl C, Ruschaupt M, Sahin Ö, Arlt D, Wiemann S, Poustka A, Sülthmann H, Korf U (2008) Contact-spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalling. *Proteomics*. 8(8):1586-94.

2007

31. Sahin Ö, Löbke C, Korf U, Appelhans H, Sülthmann H, Poustka A, Wiemann S, Arlt D (2007) Combinatorial RNAi for quantitative protein network analysis. *PNAS*. 104:6579-6584. (Highlighted in the Issue).

2006

32. Arlt D, Sahin Ö, Korf U, Loebke C, Beißbarth T, Hahne F, Wiemann S, Poustka A (2006) Modeling breast cell cycle regulation - overcoming drug resistance. *Conf Proc IEEE Eng Med Biol Soc*.1:40-3.

Book Chapters:

Mannspenger H, Uhlmann S, Korf U, Sahin Ö* (2010). Utilization of RNAi to validate antibodies for reverse phase protein arrays. *Methods in Molecular Biology* (Springer NY/Humana Press) 785: 4(45-54).